Research & Education
CURE Expert Connections
Email Sign Up
To start your customized experience click the start button
Customize your homepage by selecting specific cancer types.
Cancer of Unknown Primary
Diet and Exercise
Gastrointestinal stromal tumor
General Financial Topics
General Psychosocial Aspect Topics
Head & Neck Cancer
Mantle Cell Lymphoma
Metastatic Breast Cancer
Side Effect Management
Small Lymphocytic Lymphoma (SLL)
Advocacy & Research
Share Your Story
Newsletter Sign Up
Ovarian Cancer Heroes
Bone Health Champions
Terms & Conditions
Cure Media Group, LLC.
2 Clarke Drive
Cranbury, NJ 08512
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Part VI: How GIST and I Became Acquainted
Moving back into the light.
Part III: How GIST and I Became Acquainted
The medical team had reached some conclusions.
Part II: How Gastrointestinal Stromal Tumor (GIST) and I Became Acquainted
This is how I became hospital property.
How Gastrointestinal Stromal Tumor (GIST) and I Became Acquainted
Twenty strokes signaled that there was trouble, though no one would have suspected a tumor.
Crossing Tumor Types: BRCA Experience Points Way to New Diagnostic Paradigm
Maurie Markman, MD
It is now well recognized that the presence of a molecular abnormality shown to be actionable in one tumor type may be highly clinically relevant in other malignancies.
Targeting Gastric Cancer: Recent Advances Generate Fresh Hopes After Many Frustrations
Jane de Lartigue, PhD
In the hopes of recreating the successes achieved in other solid malignancies, researchers have evaluated many types of targeted therapy for the treatment of advanced gastric cancer.
Gastric Cancer Advocate Debbie Zelman Talks About Need for Education and Support
Debbie Zelman is the founder and president of Debbie's Dream Foundation: Curing Stomach Cancer, a nonprofit organization that is dedicated to educating and supporting patients and their families.
Updated Study Results Shows Activity for Keytruda in Gastric Cancer
Among patients with metastatic gastric cancer treated with the PD-1 inhibitor Keytruda, the agent showed promising activity, according to updated findings from the KEYNOTE-012 study presented at the Gastrointestinal Cancers Symposium.
Survivors Proclaim November as Curing Stomach Cancer Month
Why is November not named an "awareness month?" Because stomach cancer isn't only about awareness.
Cyramza Receives Second Approval to Treat Gastric Cancer
The FDA approves Cyramza (ramucirumab) in combination with paclitaxel for the treatment of advanced gastric cancer or GEJ adenocarcinoma.
Not a member?
Sign up now!
Continue without login
OPTIONAL INFORMATION: The following information helps us tailor CURE to fit your needs
Please type below what best describes your interests and click on the selection(s):
I am a:
Please list other: